ARVINAS, INC.
ARVN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ARVN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARVN
Arvinas is a clinical-stage biotechnology company focused on developing PROTAC protein degrader therapeutics, with one FDA-approved product (VEPPANU™/vepdegestrant) for ER+/HER2- breast cancer and a pipeline of candidates in oncology and neurology.
Key risk: Dependence on third-party commercialization
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 8 clinical trials for ARVINAS, INC..
Arvinas is a clinical-stage biotechnology company focused on developing PROTAC protein degrader therapeutics, with one FDA-approved product (VEPPANU™/vepdegestrant) for ER+/HER2- breast cancer and a pipeline of candidates in oncology and neurology.
- Arvinas received FDA approval for VEPPANU™ (vepdegestrant) in Q2 2026 for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer [sec_mda · as of 2026-05-11].
- As of June 30, 2026, Arvinas reported cash & equivalents of $94.3M, total revenue of $249.7M, and net income of $169.4M [sec].
- The company has received an aggregate of $933.1 million in payments primarily from collaboration partners and a licensing arrangement [sec_mda · as of 2026-05-11].
- Key pipeline candidates include ARV-393 (BCL6), ARV-102 (LRRK2), ARV-806 (KRAS G12D), and ARV-027 (polyQ-AR), all in clinical trials [sec_mda · as of 2026-05-11].
- Arvinas expects existing cash to fund planned operating expenses and capital expenditure requirements into the second half of 2028 [sec_mda · as of 2026-08-04].
What works
- Arvinas achieved its first FDA approval (VEPPANU™) in 2026, marking a major regulatory milestone and potential revenue stream [sec_mda · as of 2026-05-11].
- The company has a deep pipeline of PROTAC degraders targeting validated oncology and neurology targets, including KRAS G12D and LRRK2 [sec_mda · as of 2026-05-11].
- Arvinas has secured substantial collaboration payments ($933.1M aggregate) from partners, providing non-dilutive funding and validation of its platform [sec_mda · as of 2026-05-11].
- Cash runway is projected into H2 2028, offering a multi-year development horizon without near-term financing pressure [sec_mda · as of 2026-08-04].
What to weigh
- Arvinas has historically incurred significant operating losses and expects to continue incurring increasing expenses as it advances its pipeline [sec_mda · as of 2026-05-11].
- The company does not expect to generate product sales revenue in the near future from its pipeline candidates, relying on partnerships and financing [sec_mda · as of 2026-02-24].
- Commercialization of VEPPANU will be handled by a third-party partner, and financial terms are not yet finalized, creating uncertainty around revenue capture [sec_mda · as of 2026-05-11].
- The company faces risks from workforce reductions and potential distraction or loss of skilled personnel [sec · filed 2025-05-01].
From the filings
Quoted directly from source documents.
FDA approval of VEPPANU (vepdegestrant) for ER+/HER2- breast cancer
“In the second quarter of 2026, we announced that the FDA has approved VEPPANU™ (vepdegestrant) for the treatment of adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer”
SEC MD&A · May 11, 2026
Cash runway into H2 2028
“will enable us to fund our planned operating expenses and capital expenditure requirements into the second half of 2028”
SEC MD&A · August 4, 2026
Aggregate collaboration payments of $933.1M
“had received an aggregate of $933.1 million in payments primarily from collaboration partners and a licensing arrangement”
SEC MD&A · May 11, 2026
Pipeline includes ARV-102, ARV-806, ARV-393, ARV-027
“continue our ongoing and planned clinical trials of our product candidates, including ARV-102, our PROTAC protein degrader designed to target the LRRK2 protein, ARV-806, our PROTAC protein degrader designed to target K RAS G12D for mutated cancers, ARV-393, our PROTAC protein degrader designed to target the BCL6 protein, ARV-027”
SEC MD&A · May 11, 2026
Risks & what to watch (4)›
Key risks
- Dependence on third-party commercialization — VEPPANU pricing, access, and ex-U.S. plans will be determined by a partner, with financial terms unknown [sec_mda · as of 2026-05-11].
- Historical operating losses — Arvinas has incurred significant operating losses since inception and expects increasing expenses [sec_mda · as of 2026-05-11].
- Workforce reduction risks — Workforce reduction may impact ability to retain skilled personnel and cause distraction [sec · filed 2025-05-01].
- Need for additional capital — If unable to raise capital, Arvinas may delay or reduce programs or relinquish rights [sec_mda · as of 2026-05-11].
What to watch
- Progress of ARV-393 (BCL6) Phase 1 clinical trial [sec · filed 2026-04-29].
- Progress of ARV-102 (LRRK2) clinical trial [sec · filed 2026-04-29].
- Progress of ARV-806 (KRAS G12D) Phase 1 clinical trial [sec · filed 2026-04-29].
- Advancement of new assets toward first-in-human clinical trials [sec · filed 2026-04-29].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run ARVINAS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ARVINAS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
35.4 months
D/E 0.20 · 1% dilution
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
1 buy · 9 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
204
Total value held
$521.2M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 6,797,584 | $72.1M |
| vanguard capital management llc | 5,378,724 | $57.0M |
| vanguard portfolio management llc | 3,889,628 | $41.2M |
| d. e. shaw & co., inc. | 3,638,567 | $38.6M |
| armistice capital, llc | 1,978,000 | $21.0M |
| two sigma investments, lp | 1,832,114 | $19.4M |
| state street corp | 1,828,472 | $19.4M |
| geode capital management, llc | 1,557,107 | $16.5M |
| jacobs levy equity management, inc | 1,441,521 | $15.3M |
| citadel advisors llc | 1,227,488 | $13.0M |
Showing top 10 of 204 institutional holders of ARVINAS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 8.0%
- Days to cover
- 5.8
- Shares short
- 4,417,179
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARVN short interestGovernance
Frequently asked questions
What is the AI investment thesis for ARVINAS, INC.?
Arvinas is a clinical-stage biotechnology company focused on developing PROTAC protein degrader therapeutics, with one FDA-approved product (VEPPANU™/vepdegestrant) for ER+/HER2- breast cancer and a pipeline of candidates in oncology and neurology.
What is ARVINAS, INC.'s lead drug candidate?
ARVINAS, INC.'s most advanced tracked candidate is ARV-102 (Phase 2) for Neurodegenerative diseases including Parkinson's Disease (PD) and progressive supranuclear palsy (PSP).
Who is the CEO of ARVINAS, INC.?
Dr. Randy Teel Ph.D. is the chief executive officer of ARVINAS, INC. (ARVN).
Where is ARVINAS, INC. headquartered?
ARVINAS, INC. (ARVN) is headquartered in New Haven, CT, United States.
What therapeutic areas does ARVINAS, INC. focus on?
ARVINAS, INC. develops therapies across Oncology, Neurology, Immunology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.